Details of the Drug Reposition

General Information of This Drug (ID: DMWKSFY)

• Drug Name: GSK3511294 (DMWKSFY)
• Synonyms: depemokimab
• Drug Type: Monoclonal antibody

Information on Drug Reposition of This Drug

4 Phase 3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Hypereosinophilic syndrome	DISVK62S	2A20.3	Phase 3	[1]
Eosinophilic granulomatosis with polyangiitis	DIS7ITOG	4A44.A2	Phase 3	[2]
chronic rhinosinusitis with nasal polyps	DISFH0LT	CA0A	Phase 3	[3]
Asthma	DISW9QNS	CA23	Phase 3	[4]

References

• [1] ClinicalTrials.gov (NCT05334368) A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Depemokimab in Adults With Hypereosinophilic Syndrome (HES). U.S.National Institutes of Health.
• [2] ClinicalTrials.gov (NCT05263934) A 52-week, Randomized, Double-blind, Double-dummy, Parallel-group, Multi-centre, Non-inferiority Study to Investigate the Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) Receiving Standard of Care (SoC) Therapy. U.S.National Institutes of Health.
• [3] ClinicalTrials.gov (NCT05281523) A Randomised, Double-blind, Parallel Group Phase III Study to Assess the Efficacy and Safety of 100 mg SC Depemokimab in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) - ANCHOR-2 (depemokimAb iN CHrOnic Rhinosinusitis). U.S.National Institutes of Health.
• [4] ClinicalTrials.gov (NCT05243680) A Multi-centre, Single Arm, Open-label Extension Study to Evaluate the Long-term Safety of GSK3511294 (Depemokimab) in Adult and Adolescent Participants With Severe Asthma With an Eosinophilic Phenotype From Studies 206713 or 213744. U.S.National Institutes of Health.